Skip to content

Neuromodulation Treatment of Vestibular Migraines

Neuromodulation Treatment of Vestibular Migraines

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02866084
Enrollment
0
Registered
2016-08-15
Start date
2016-09-28
Completion date
2019-05-31
Last updated
2019-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Headache

Keywords

vestibular migraines, dizziness, migraine headache

Brief summary

This is a non-randomized pilot study to test the efficacy of neuromodulation via caloric stimulation on vestibular migraines. All subject who meet the study criteria will be in an active treatment group. All subjects will report the frequency of the migraines and undergo periodic testing of symptoms.

Detailed description

This is a non-blinded, non-randomized pilot study of individuals with vestibular migraines. The goal is to test the efficacy of neuromodulation on both migraine and dizziness symptoms in patients with documented vestibular migraines. Treatment will consist of 9 months of active treatment followed by 3 months of observation. The active treatment requires two daily 20 minute sessions wearing a device over the ears that delivers a very small amount of warm air to the ears. All subjects will undergo a series of tests at baseline and at discrete intervals during the 1 year of observation. Primary and Secondary endpoints are listed below:• Primary Efficacy Endpoints 1. Reduction in the frequency and severity of migraine headaches (self reported in pain diary) 2. Reduction in the frequency and intensity of perceived vestibular symptoms (Dizziness Handicap Inventory (DHI), Activity Balance confidence scale (ABC), Oscillopsia Test, Symptoms questionnaire), OVRT Goggle profile. Secondary Efficacy Endpoints for the Pilot Study 1. Improvement in sleep quality and/or quantity as assessed by the Epworth Sleep Scale. 2. Improvement in quality of life as assessed by the HIT-6 survey. 3. Improvement in mood/anxiety as assessed with the T2 Mood Tracker app (National Center for Telehealth & Technology).

Interventions

DEVICEDevice

The following parameters will be set for active treatments using the CVS Device: * A standardized CVS time-varying waveform lasting approximately 19 minutes will be used. Treatments will be administered up to twice daily. The two daily treatments should ideally be separated by at least one hour. * The waveform schedule will consist of a warm sawtooth delivered to one ear and a cold sawtooth delivered to the other ear. The warm sawtooth will go from body temperature to 42 °C, and the cold sawtooth will go from body temperature to 17 °C. The two waveforms will be delivered simultaneously, but will have different oscillation frequencies.

Sponsors

Scion NeuroStim
CollaboratorINDUSTRY
University of Miami
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

1. Adults, between the ages of 18 and 75 who have been diagnosed with VM least 3 months prior to entering into the study. 2. The Investigator must have confidence in the patient's ability to reliably use the CVS Device and complete the requirements of the study.

Exclusion criteria

1. are pregnant 2. have a history of cardiovascular disease 3. work night shifts 4. have a history of unstable mood disorder or unstable anxiety disorder 5. use a hearing aid 6. have a cochlear implant 7. abuse alcohol or other drugs 8. are experiencing Medication Overuse Headaches (individuals with respect to whom the Investigator is concerned that analgesic abuse is involved based on the ICHD-II guidelines). 9. have had eye surgery within the previous three months or ear surgery within the previous six months 10. have active ear infections or a perforated tympanic membrane 11. have participated in another clinical trial within the last 30 days or are currently enrolled in another clinical trial

Design outcomes

Primary

MeasureTime frameDescription
Dizziness Handicap InventoryUntil study completion up to 12 monthsQuestionnaire of dizziness symptoms
Headache Impact TestUntil study completion up to 12 monthsHeadache questionnaire
Activities Balance Confidence IntervalUntil study completion up to 12 monthsDizziness questionnaire
OVRT TestingUntil study completion up to 12 monthsOculomotor, vestibular, and reaction time tests

Secondary

MeasureTime frameDescription
Epworth Sleepiness ScaleUntil study completion up to 12 monthsSleepiness questionnaire
T2 Mood Tracker appUntil study completion up to 12 monthsApp to assess mood and anxiety

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026